San Diego-based Viking Therapeutics marked alone as a serious competitor within the weight loss drug sector in February immediately after revealing promising data from a mid-stage demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when specified as a weekly injection and in March the company unveil